| Autor: |
Keane, C., Nourse, J. P., Crooks, P., Nguyen-Van, D., Mutsando, H., Mollee, P., Lea, R. A., Gandhi, M. K. |
| Předmět: |
|
| Zdroj: |
Internal Medicine Journal; Oct2012, Vol. 42 Issue 10, p1113-1119, 7p, 2 Charts, 1 Graph |
| Abstrakt: |
Background Recent reports suggest genetic polymorphisms influence susceptibility to rituximab-induced late-onset neutropenia ( LON), which in turn may be a predictor of good outcome in B-cell lymphoma. Aims We report the largest study to date assessing FCGR3A- V158F polymorphisms in diffuse large B-cell lymphoma ( DLBCL) treated with cyclophosphamide/hydroxydaunorubicin/ Oncovin (vincristine)/prednisone/rituximab ( CHOP- R). The influence of C1qA- A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. Methods 115 DLBCL patients treated with CHOP-R were compared with 105 healthy White people controls with regards to FCGR3A- V158F and C1qA- A276G polymorphisms. LON incidence and event-free and overall survival ( EFS and OS) were analysed for linkage to either polymorphism. Results The FCGR3A- V158F but not the C1qA- A276G polymorphism influenced the risk of developing LON. 50% of FCGR3A-158 V/ V patients experienced LON. In contrast, only 7% V/ F and 2% F/ F experienced LON. The FCGR3A-158 V/ V genotype was associated with LON compared with V/ F ( P = 0.028) and F/ F genotypes ( P = 0.005). Although no patients with either LON or FCGR3A-158 V homozygosity relapsed compared with 33% FCGR3A-158F/ F and 21% non- LON, this did not translate into improved EFS or OS. Conclusions Polymorphic analysis may be a predictive tool to identify those at high risk of LON. Prospective studies are required to establish definitively if LON or FCGR3A-158 V/ V genotype influences outcome. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text